Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Cybin Inc N.CYBN

Alternate Symbol(s):  CYBN

Healthcare Drug Manufacturers - Specialty & Generic Psychedelics
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary... see more

Bullboard (NEO:CYBN)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Post by thorgb1on Sep 27, 2023 9:25am

News: Small Pharma reports positive Phase 1b results….

News here: https://www.businesswire.com/news/home/20230927069776/en/  
121
Comment by thorgb1on Sep 26, 2023 9:35am

RE:A double in 10 days

Best if breed in the pyschadelic space with a recent huge investment by a U.S. hedge fund that hits home runs with pharma investments.
135
Discussion
Post by Yanks23on Sep 25, 2023 6:31pm

A double in 10 days

what is going on with this Co?
186
Discussion
Post by Yanks23on Sep 25, 2023 2:50pm

A double in 10 days

what is going on with this Co?
123
Post by thorgb1on Sep 21, 2023 7:55am

News: patient enrolment for phase 3 study complete…..

Advancing towards breakthrough status. News here: https://www.businesswire.com/news/home/20230921411645/en/
133
Post by thorgb1on Sep 05, 2023 10:09am

News: another US patent granted….

29 patents granted and another 150 pending. News here: https://www.businesswire.com/news/home/20230905527566/en/
139
Post by thorgb1on Aug 28, 2023 11:18am

NEWS: Acquiring Small Pharma....

News here:  Cybin to Acquire Small Pharma Inc. | Business Wire
206
Post by thorgb1on Aug 28, 2023 10:15am

Halted pending news….

Give us something good......
141
Post by thorgb1on Aug 15, 2023 8:53am

News: Patent Granted….

https://www.businesswire.com/news/home/20230814537498/en/
120
Post by whytestockson Aug 04, 2023 11:00am

Cybin Announces Closing of Overnight Marketed Public Offerin

NEWS: $CYBN Cybin Announces Closing of Overnight Marketed Public Offering of UnitsCybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), ...more  
164
Comment by Yanks23on Jul 06, 2023 4:34pm

RE:Cannacord Genuity…,

Did they give a timeline for that target
121
Discussion
Post by thorgb1on Jul 05, 2023 6:06pm

Cannacord Genuity…,

$6 target, out this morning
166
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities